| The Ministry of Health, the Regions, and AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 肝臓
> 肝疾患：ほとんどの種類 | 規制上のパートナーシップ
> 規制機関との連携 | 10,000 | National | Regularly | 115023591745 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 規制上のパートナーシップ
> 規制機関との連携 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | レア
> 希少疾患：代謝性/ライソゾーム性 | 規制上のパートナーシップ
> 規制機関との連携 | 1,000 | National | Regularly | 115050896715 |
| Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services], Ministry of Health, Lazio Region. | 呼吸器
> 呼吸器：ほとんどの状態 | 規制上のパートナーシップ
> 規制機関との連携 | 5,000 | National | Sometimes | 115052531440 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 規制機関との連携 | 100,000 | National | Regularly | 115057561938 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 規制機関との連携 | 100,000 | National | Regularly | 115057561938 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | ハート
> 心不全 | 規制上のパートナーシップ
> 規制機関との連携 | 10,000 | National | Regularly | 115057865983 |
| Approval of medicinal products by AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 呼吸器
> 肺高血圧症 | 規制上のパートナーシップ
> 規制機関との連携 | 100 | National | Rarely | 115060569246 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 腎臓
> 腎臓病 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | Regional | Sometimes | 114997535217 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原発性免疫不全症 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Regularly | 115020417471 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | がん
> がん：乳房 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | We do not communicate with patients directly | National | Sometimes | 115035044046 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products. | レア
> 希少疾患：腎臓 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100 | National | Rarely | 115057369547 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Regularly | 115057561938 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | レア
> まれな疾患：遺伝性 | 規制上のパートナーシップ
> マーケティング承認申請への貢献 | 100,000 | International | Regularly | 119078073632 |
| Our regional representatives participate in the regional diabetes technical working groups. | 内分泌
> 糖尿病（1型および2型の両方） | 規制上のパートナーシップ
> 臨床ガイドライン策定機関への関与 | 10,000 | National | No | 115028521635 |
| We requested meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] on two occasions; one such request, in 2023, was successful. | がん
> がん：胆管 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Rarely | 114996625156 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 腎臓
> 腎臓病 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | Regional | Sometimes | 114997535217 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | レア
> 嚢胞性線維症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 115005109524 |
| Through the Ministry of Health and the Lombardy Region. | HIV
> HIV | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | Local | Regularly | 115006694528 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原発性免疫不全症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 115020417471 |
| We engage in dialogue with the Regional Authority and with the ASP [Aziende Sanitarie Provinciali – Provincial Health Authorities]. | 出血
> 血友病 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100 | Regional | Regularly | 115037242647 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型および2型の両方） | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 神経学的
> 多発性硬化症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Regularly | 115038849633 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | レア
> 希少疾患：代謝性/ライソゾーム性 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Regularly | 115050896715 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Regularly | 115057561938 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | レア
> 希少疾患：肝臓 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100 | National | Rarely | 115057832320 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | ハート
> 心不全 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 115057865983 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition. | がん
> がん：血液 | 規制上のパートナーシップ
> 他の医療擁護者と | 1,000 | National | Rarely | 115006753491 |
| Through the UNIAMO [Unione Italiana delle Associazioni di Malati – Italian Federation of Rare Disease Patient Organisations] Federation, with which we are affiliated. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 他の医療擁護者と | 100 | National | Regularly | 115055436186 |
| Through a network of associations. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 他の医療擁護者と | 100 | National | Regularly | 115057092350 |
| We are actively campaigning for the amendment or abolition of Nota 99 [Nota 99 is the Italian Medicines Agency (AIFA) reimbursement guideline for Chronic Obstructive Pulmonary Disease (COPD) maintenance therapies. It regulates the prescription of inhalers, ensuring appropriate diagnosis through spirometry while detailing which treatments GPs can initiate or repeat]. We are also campaigning for vaccination against Respiratory Syncytial Virus (RSV). | 呼吸器
> 喘息とCOPD | 政策と法律への影響
> 医療政策と法律に影響を与える | 5,000 | National | Regularly | 114996865765 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 全般的な健康状態
> 肥満 | 政策と法律への影響
> 医療政策と法律に影響を与える | 10,000 | National | Regularly | 115012927513 |
| Cardiovascular Alliance — Ministry of Health. | 心臓血管
> 心臓血管系：ほとんどの種類 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100 | Regional | Sometimes | 115028352096 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | ボーン
> ボーン：その他 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100 | National | Regularly | 115037246562 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100,000 | National | Regularly | 115057561938 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | ボーン
> ボーン：その他 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 100 | National | Regularly | 115037246562 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型および2型の両方） | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神経学的
> 多発性硬化症 | 政策と法律への影響
> 国会議員や政治指導者を動員する | 100,000 | National | Regularly | 115038849633 |
| Cross-Party Parliamentary Group — IVT [Intravitreal Therapy] Technical Working Group. Cataract Technical Working Group — Regional Partnerships — Local Activities. | 視覚障害
> 視覚障害 | 政策と法律への影響
> 国会議員や政治指導者を動員する | 1,000 | National | Regularly | 115056238448 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 全般的な健康状態
> 肥満 | 政策と法律への影響
> 公衆衛生法の立案に貢献する | 10,000 | National | Regularly | 115012927513 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | ハート
> 心不全 | 政策と法律への影響
> 医療における障壁・異常への対処 | 10,000 | National | Regularly | 115057865983 |
| Market authorisation for "Koselugo" [used to treat neurofibromatosis type 1 (NF1)] should be extended to adult patients, given that it is currently approved only for paediatric cases where surgery is not an option. | 神経学的
> 神経線維腫症（NF） | 政策と法律への影響
> 医療における障壁・異常への対処 | 1,000 | National | Sometimes | 115060431887 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 価格設定と手頃な価格の擁護
> 薬価の追跡・監視/医薬品不足 | 100 | Local | Regularly | 115037563159 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 内分泌
> 糖尿病（1型および2型の両方） | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 1,000 | Local | Sometimes | 115023236354 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型および2型の両方） | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100 | Local | Sometimes | 115037371533 |
| Our work focuses on securing reimbursement for medicines, not on pricing. | 神経変性
> 認知症 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100,000 | National | Rarely | 115060441597 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 価格設定と手頃な価格の擁護
> 啓発キャンペーンへの参加 | 100 | Local | Regularly | 115037563159 |
| Competitive tender for diabetes medical devices and supplies. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | Regional | Rarely | 114997517950 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾患：ほとんどの種類 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | レア
> 嚢胞性線維症 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 10,000 | National | Regularly | 115005109524 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition [blood cancers]. | がん
> がん：血液 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | National | Rarely | 115006753491 |
| Extension of the indications for the use of Baqsimi, indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged one year and above with diabetes mellitus. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | Regional | Sometimes | 115021346889 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | Local | Sometimes | 115023236354 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 視覚障害
> 視神経脊髄炎 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | National | Regularly | 115024933081 |
| Meetings with FG [Focus Group] to improve community-based diabetology services. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | Local | Sometimes | 115032223368 |
| We are seeking early access for the drug vorasidenib [oral cancer therapy for people with gliomas]. | がん
> がん：脳 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100 | National | Sometimes | 115050882510 |
| Formal request letters to expedite access to medicines. | がん
> がん：婦人科系 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | National | Sometimes | 115055638865 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Regularly | 115057561938 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] or regional health authorities regarding delays in the market access of medicines. | がん
> がん：婦人科系 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | National | Rarely | 115060470442 |
| We are campaigning for vaccination against Respiratory Syncytial Virus (RSV) [in Italy]. | 呼吸器
> 喘息とCOPD | アクセス経路の改善
> より広いワクチンアクセスを推進する | 5,000 | National | Regularly | 114996865765 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 内分泌
> 糖尿病（1型および2型の両方） | アクセス経路の改善
> アクセスと管理における格差への対処 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 視覚障害
> 視神経脊髄炎 | アクセス経路の改善
> アクセスと管理における格差への対処 | 100 | National | Regularly | 115024933081 |
| We are an integral part of the Innovative Medicines Group of the Veneto Region [part of Veneto Region's governance structure for evaluating and managing access to innovative medicines]. | がん
> がん：血液 | アクセス経路の改善
> アクセスと管理における格差への対処 | 1,000 | National | Regularly | 115053421236 |
| Regional disparities in access to treatment and enrolment in therapeutic management plans. | 神経学的
> てんかん | アクセス経路の改善
> アクセスと管理における格差への対処 | 1,000 | Regional | Sometimes | 115063172483 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | ボーン
> ボーン：その他 | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 100 | National | Regularly | 115037246562 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products [for rare kidney conditions]. | レア
> 希少疾患：腎臓 | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 100 | National | Rarely | 115057369547 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | レア
> 希少疾患：肝臓 | 診断と薬の配達
> 安全で効果的な薬の使用を確保する | 100 | National | Rarely | 115057832320 |
| Our regional representatives participate in the regional diabetes technical working groups. | 内分泌
> 糖尿病（1型および2型の両方） | 診断と薬の配達
> 臨床ガイドラインの策定に参加する | 10,000 | National | No | 115028521635 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. | 神経学的
> 多発性硬化症 | 診断と薬の配達
> 臨床ガイドラインの策定に参加する | 100,000 | National | Regularly | 115038849633 |
| By participating in the regional coordination body that sits on the regional working table. | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100 | Regional | Rarely | 115019671886 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100,000 | National | Regularly | 115031446886 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100 | Local | Regularly | 115037426004 |
| We maintain regular contact with the relevant offices of the Tuscany Regional Authority. | 出血
> 血友病 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100 | Regional | Regularly | 115043798242 |
| Represent patients before national and European regulatory bodies — including AIFA [Agenzia Italiana del Farmaco, the Italian Medicines Agency] and EMA [European Medicines Agency] — as well as national health institutions and local authorities. | レア
> 希少疾患：代謝性/ライソゾーム性 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 1,000 | National | Regularly | 115050896715 |
| In an advisory capacity, when consulted by the local and regional health authority (Azienda Sanitaria Locale). | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100 | Local | Rarely | 115060756578 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | レア
> まれな疾患：遺伝性 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100,000 | International | Regularly | 119078073632 |
| By participating in the regional coordination body that sits on the regional working table. | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100 | Regional | Rarely | 115019671886 |
| Participated alongside Public Institutions in the Stroke Observatory. | 脳血管
> ストローク | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 5,000 | National | Regularly | 115019690819 |
| Participated alongside Public Institutions in the Stroke Observatory. | 脳血管
> ストローク | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 5,000 | National | Regularly | 115019690819 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100,000 | National | Regularly | 115031446886 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100 | Local | Sometimes | 115037371533 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 内分泌
> 糖尿病（1型および2型の両方） | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100 | Local | Regularly | 115037426004 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神経学的
> 多発性硬化症 | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 100,000 | National | Regularly | 115038849633 |
| Healthcare protection, consumer protection, and other related areas. | 全般的な健康状態
> 医療提供 | 患者の権利の擁護/生活の質の向上
> 患者体験の保護・改善 | 1,000 | Regional | Regularly | 115038525050 |
| Documentation requirements for the renewal of driving licences for individuals with diabetes. | 内分泌
> 糖尿病（1型および2型の両方） | 患者の権利の擁護/生活の質の向上
> 患者体験の保護・改善 | Do not know | Regional | Sometimes | 115046244188 |
インタラクション
アクションと支援活動
31 メンション
